CD8A and neoplasm: Although the use of immunotherapy in PDAC patients faces a few challenges, including the “cold” tumor microenvironment (TME), which is marked by myeloid cell aggregation, a dearth of CD8+ T cells, and minimal activation marker expression, these factors suggest a significant impairment or absence of adaptive T cell immunity (5).